Table 3.
Comparison of the prevalences of ring/tramline opacities in 59 inpatients with and without (1) a chronic cough, (2) a cough productive of sputum, (3) progressive dyspnoea, (4) a primary respiratory cause for admission and (5) a history of treatment with HAART
| Clinical feature present | Clinical feature absent | p-value | |
|---|---|---|---|
| Cough (n = 16) | 11/16 (69%) | 25/43 (58%) | 0.46 |
| Productive cough (n = 8) | 5/8 (62%) | 31/51 (61%) | 0.93 |
| Progressive dyspnoea (n = 31) | 21/31 (68%) | 15/28 (54%) | 0.27 |
| Respiratory admission (n = 36) | 21/36 (58%) | 15/23 (65%) | 0.60 |
| HAART therapy (n = 21) | 12/21 (57%) | 24/38 (63%) | 0.65 |
The table describes the prevalence of ring/tramline opacities in patients with and without specific clinical features; for example, ring/tramline opacities were present in 11/16 (69%) patients with a chronic cough but also in 25/43 (58%) patients without a chronic cough. HAART, highly-active antiretroviral therapy.